SUMMIT, NJ (TheStreet) -- Celgene (CELG) reported positive results Thursday from a large phase III study seeking to establish the company's multiple myeloma drug as the preferred treatment for newly diagnosed patients.
The so-called MM-020 study achieved its primary endpoint demonstrating that treatment with a combination of Revlimid plus low-dose dexamethasone significantly delayed the time before patients' cancer returned compared to treatment with a three-drug chemotherapy regimen known as MPT, Celgene said.
Details from the MM-020 study were not released Thursday but will be presented at the American Society of Hematology annual meeting in December.
Based on results from the MM-020 study, Celgene plans to submit regulatory filings in Europe and the U.S. seeking to expand Revlimid's label to include treatment for newly diagnosed multiple myeloma patients, the company said.Celgene shares rose 3% to $129.01 in pre-market trading. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV